Adaptive Biotechnologies Q4 Results Exceed Expectations, Analysts Boost 2026 Revenue Forecasts
ByAinvest
Sunday, Feb 8, 2026 8:11 am ET1min read
ADPT--
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) reported better-than-expected full-year results, with revenues of $277m leading estimates by 4.1% and statutory losses of $0.39 per share smaller than expected. Analysts have updated their earnings model, forecasting 2026 revenues of $277.2m and losses of $0.49 per share, up from previous estimates. The consensus price target remains at $20.86, with a relatively close grouping of estimates.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet